Back to Journals » ImmunoTargets and Therapy » Volume 5 » default
ImmunoTargets and Therapy
- View all (339)
- Volume 15, 2026 (37)
- Volume 14, 2025 (90)
- Volume 13, 2024 (56)
- Volume 12, 2023 (14)
- Volume 11, 2022 (6)
- Volume 10, 2021 (30)
- Volume 9, 2020 (27)
- Volume 8, 2019 (5)
- Volume 7, 2018 (10)
- Volume 6, 2017 (8)
- Volume 5, 2016 (8)
- Volume 4, 2015 (17)
- Volume 3, 2014 (14)
- Volume 2, 2013 (13)
- Volume 1, 2012 (3)
Archive: Volume 5, 2016
Insights into the pathogenesis of Langerhans cell histiocytosis: the development of targeted therapies
Hutter C, Minkov M
ImmunoTargets and Therapy 2016, 5:81-91
Published Date: 12 October 2016
Toll-like receptors in the pathogenesis of autoimmune diseases: recent and emerging translational developments
Duffy L, O’Reilly SC
ImmunoTargets and Therapy 2016, 5:69-80
Published Date: 22 August 2016
Prion diseases: immunotargets and therapy
Burchell JT, Panegyres PK
ImmunoTargets and Therapy 2016, 5:57-68
Published Date: 16 June 2016
The role of adipokines in chronic inflammation
Mancuso P
ImmunoTargets and Therapy 2016, 5:47-56
Published Date: 23 May 2016
Immunotherapy for tuberculosis: future prospects
Abate G, Hoft DF
ImmunoTargets and Therapy 2016, 5:37-45
Published Date: 20 April 2016
Current perspectives on the immunopathogenesis of systemic sclerosis
Fuschiotti P
ImmunoTargets and Therapy 2016, 5:21-35
Published Date: 11 April 2016
Current and emerging treatment options in the management of lupus
Jordan N, D’Cruz D
ImmunoTargets and Therapy 2016, 5:9-20
Published Date: 2 March 2016
Role of romiplostim in splenectomized and nonsplenectomized patients with immune thrombocytopenia
Perdomo J
ImmunoTargets and Therapy 2016, 5:1-7
Published Date: 22 February 2016